21 Jun 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Indonesian market for cardiac rhythm management earned revenues of $1.75 million in 2011 and is estimated to reach $4.15 million in 2016 at a compound annual growth rate of 18.9 per cent, according to Frost & Sullivan.
Indonesia has a high prevalence of both communicable and non-communicable diseases; among non-communicable diseases, cardiovascular disease's incidence is 7.2 per cent of the total population of 247 million and it is also the fourth leading cause of mortality. Of these, 2.1 million suffer from disorders caused by the rhythm of heart, signifying vast opportunities for the cardiac rhythm management (CRM) market on a small base.
The occurrence of cardiovascular diseases is on the rise due to sedentary lifestyles, unhealthy eating habits and urbanization. However, changes in healthcare services legislation, revamp in health insurance policies, an aging population, affluent and dormant life style, smoking and the urge to be treated will boost the Indonesian CRM market.
In 2011, single-chamber pacemakers were the most popular device for CRM due to their low cost, familiarity and simplicity of implantation.
"Both hospitals and healthcare professionals have indicated a preference for pacemakers, making it the largest segment, with a sale of 417 units, accounting for 49.6 per cent of the Indonesian CRM market," says Frost & Sullivan's Consultant, Poornima Srinivasan.
Pacemakers will gain further traction with its use in cardiac resynchronization therapy due to the product's success rates, efficacy and longevity.
Currently, there are limited interventional cardiology and electrophysiology centres to perform cardiac rhythm implants.
"To meet the needs of the growing incidence, the Indonesian government is encouraging private hospitals and foreign participants to establish hospitals in the country," notes Srinivasan.
"As the rising wealth and population growth necessitate quality healthcare services in Indonesia, the government has decided to extend the maximum limit for foreign ownership from 47 percent to 67 percent. As a result of this legislation, more foreign hospitals with sophisticated technologies and infrastructure are expected to invest in Indonesia," says Eugene van de Weerd, Country Director, Frost & Sullivan - Indonesia. "Such a move is expected to result in more cardiac, oncological, and other surgeries taking place within the country, thereby curtailing the need for medical treatment abroad." Eugene concluded.